News

Ophthalmology Times33m
Harrow enters into agreement with Samsung Bioe for commercial rights to its ophthalmology biosimilar portfolio
Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...